Novavax to Move Forward With Covid-19-Flu Vaccine

“The Phase 1 clinical trial is designed to evaluate the safety, reactogenicity, and immunogenicity of ARCT-2304 as a potential vaccine to protect against the highly pathogenic H5N1 avian influenza ...
and stand-alone influenza vaccine candidates. The FDA has cleared the Company to begin enrolling the planned Phase 3 ...
A fresh wave of disinformation about vaccines is flaring amid the 2024 campaign. The FDA's top vaccine official believes ...
On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved the first influenza (flu) vaccine for at‑home use. The vaccine, ...
The aTIV vaccine provides better protection against influenza-related medical encounters than the HD-TIV vaccine in high-risk older adults.
Seasonal influenza epidemics impose substantial burdens on healthcare systems and cause >5 million hospitalizations of adults each year.
Animal health companies are developing vaccines that improve the breadth and effectiveness of protection against avian ...
The first inactivated influenza vaccine was monovalent (influenza A). In 1942, a bivalent vaccine was produced after the discovery of influenza B. It was later discovered that influenza ...
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...